RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
RenovoRx has completed patient enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, positioning the company for a potential pivotal data readout in the second half of 2027. The trial compares intra-arterial gemcitabine delivered via RenovoCath to standard systemic chemotherapy, with 78 of the required 86 survival events already observed as of the release date.
Key figures
- Revenue
- 563000
- Drug Name
- intra-arterial gemcitabine (IAG)
- Phase Of Trial
- Phase III
- Revenue 2025
- 1100000
- Events occurred
- 78
- Events required
- 86
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.